Advanced development of hemorrhagic

Ended Definitive Contract Awarded Last action

Contract number
W9113M10C0057
Awardee
Awarding agency
Obligated
$52,187,135

Award facts

Opportunity
Contract value 33% obligated
  • $122,547,197.24 Current, with exercised options
  • $157,226,529.24 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
NAICS code
541711 Research and Development in Biotechnology
PSC
AN13 Health R&D Services; Health Care Services; Experimental Development
Set-aside
No set-aside
Competition
Full and Open Competition · 10 offers Negotiated Proposal / Quote
Pricing
Cost Plus Incentive
Place of performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00044 $0
Close Out P00043 -$559,672
Funding Only Action P00042 -$17,185,180
Other Administrative Action P00041 $0
Other Administrative Action P00040 $0
Other Administrative Action P00039 $0
Other Administrative Action P00038 $0
Change Order P00037 $1,690,592
Funding Only Action P00036 $14,988,769
Supplemental Agreement for work within scope P00035 $183,500
Supplemental Agreement for work within scope P00034 $0
Change Order P00033 $2,250,000
Exercise an Option P00032 $0
Funding Only Action P00031 $6,341,423
Supplemental Agreement for work within scope P00030 $658,577
Other Administrative Action A00002 $0
Supplemental Agreement for work within scope P00029 $0
Supplemental Agreement for work within scope P00028 $0
Supplemental Agreement for work within scope P00026 $0
Other Administrative Action P00027 $0
Supplemental Agreement for work within scope P00025 $2,100,000
Funding Only Action P00024 $6,286,883
Other Administrative Action P00023 $5,873,551
Supplemental Agreement for work within scope P00022 $0
Supplemental Agreement for work within scope P00021 $0
Funding Only Action P00020 $1,700,000
Funding Only Action P00019 $2,000,000
Supplemental Agreement for work within scope P00018 $0
Supplemental Agreement for work within scope P00017 $0
Supplemental Agreement for work within scope P00016 $0
Supplemental Agreement for work within scope P00015 $0
Supplemental Agreement for work within scope P00014 $0
Other Administrative Action P00013 $0
Change Order P00012 $0
Funding Only Action P00011 -$8,889,187
Other Administrative Action P00010 $0
Funding Only Action P00009 $0
Funding Only Action P00008 $10,569,177
Funding Only Action P00007 $2,920,010
Change Order P00006 $0
Funding Only Action P00005 $3,950,000
Supplemental Agreement for work within scope P00004 $0
Funding Only Action P00003 $3,000,000
Funding Only Action P00002 · Advanced development of hemorrhagic fever virus therapeutic $4,553,366
Other Administrative Action P00001 $0
Original award $9,755,326
Show all 46

Quick answers

Who was awarded contract W9113M10C0057?

W9113M10C0057 was awarded to Arbutus Biopharma Corporation by ACC Aberdeen Proving Ground (Army Contracting Command) on July 14, 2010.

How much is contract W9113M10C0057 worth?

The government has obligated $52,187,135 on W9113M10C0057. Its current value, with exercised options, is $122,547,197. Its potential value, with all options, is $157,226,529.

Which agency awarded contract W9113M10C0057?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W9113M10C0057, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W9113M10C0057 competed?

The extent of competition for W9113M10C0057 was full and open competition. The government received 10 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login